Ear Nose Throat Technologies
VenSure Balloon Sinus Dilation System and Cube™ Navigation System Are Commercially Available in the U.S.
With the launch of our VenSure Balloon Sinus Dilation System and Cube 4D Navigation system with VirtuEye, “Intersect ENT is transforming to become a more diversified, integrated and evidence-based growth company participating across the continuum of care in CRS,” said Thomas A. West, President and Chief Executive Officer of Intersect ENT.
Intersect ENT EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
EXPAND is a prospective, randomized, single-blind, intra-patient controlled, post-market clinical trial enrolling approximately 80 patients in the United States.
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402: Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
CMS’s recent decisions will also clearly differentiate coding for SINUVA and PROPEL, two very different products. This will serve to simplify and streamline coding and reimbursement across our portfolio and will support evidence-based and cost-effective care across the continuum of need in chronic rhinosinusitis.
New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant Launches: Reports Intersect ENT
Intersect ENT announces U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant.
CMS Approves Coding Application for PROPEL Sinus Implant: Approval Establishes New S Code for PROPEL to Facilitate Specific Coding & Payment
“CMS’s agreement, at our request, to assign separate codes to SINUVA and PROPEL reflects and supports our deliberate strategy to leverage Intersect ENT’s proprietary drug-eluting sinus stent technology platform while, at the same time, broadening our portfolio of therapeutic offerings, clinical indications, and health economic data to support evidence-based and cost-effective care across the continuum of need in chronic rhinosinusitis,” notes Thomas A. West, President and CEO of the company.